{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T12:33:03Z","timestamp":1773145983208,"version":"3.50.1"},"reference-count":26,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2002,8,12]],"date-time":"2002-08-12T00:00:00Z","timestamp":1029110400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arthritis &amp; Rheumatism"],"published-print":{"date-parts":[[2002,8,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>To determine whether serum \u03b2<jats:sub>2<\/jats:sub>\u2010glycoprotein I antibody (anti\u2010\u03b2<jats:sub>2<\/jats:sub>GPI) detection improves identification of pediatric subjects at risk for antiphospholipid syndrome (APS).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Serum antiphospholipid antibodies (aPL) were identified by anticardiolipin enzyme\u2010linked immunosorbent assay (ELISA), lupus anticoagulant assays, and syphilis screening in children with primary APS, systemic lupus erythematosus (SLE), or SLE plus APS. Anti\u2010\u03b2<jats:sub>2<\/jats:sub>GPI level and isotype were determined by \u03b2<jats:sub>2<\/jats:sub>GPI ELISA and correlated with clinical manifestations and other aPL assays.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>One hundred\u2010ten subjects under 22 years of age and of mixed ethnicity were evaluated. Fifty\u2010seven had SLE (including 14 with APS), 25 had primary APS, 16 had SLE\u2010like APS, 6 were healthy children with aPL detected incidentally, 4 had other rheumatic diseases and 2 had other conditions. Anti\u2010\u03b2<jats:sub>2<\/jats:sub>GPI were detected in 48% of SLE subjects and did not improve aPL detection over standard tests. Anti\u2010\u03b2<jats:sub>2<\/jats:sub>GPI were associated with stroke (<jats:italic>P<\/jats:italic> = 0.014), but not with other APS manifestations, and were rarely detected in primary APS. Among subjects with APS manifesting as chronic thrombocytopenia, anti\u2010\u03b2<jats:sub>2<\/jats:sub>GPI distinguished subjects with SLE from those with primary APS.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>With the exception of stroke, anti\u2010\u03b2<jats:sub>2<\/jats:sub>GPI detection does not improve identification of pediatric APS over that of traditional aPL assays. Anti\u2010\u03b2<jats:sub>2<\/jats:sub>GPI are rare in pediatric primary APS, but may predict evolution of chronic thrombocytopenia to SLE.<\/jats:p><\/jats:sec>","DOI":"10.1002\/art.10510","type":"journal-article","created":{"date-parts":[[2002,10,6]],"date-time":"2002-10-06T12:12:48Z","timestamp":1033906368000},"page":"414-420","source":"Crossref","is-referenced-by-count":44,"title":["Anti\u2013\u03b2<sub>2<\/sub>\u2010glycoprotein I antibodies in pediatric systemic lupus erythematosus and antiphospholipid syndrome"],"prefix":"10.1002","volume":"47","author":[{"given":"Emily","family":"von Scheven","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David V.","family":"Glidden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa E.","family":"Elder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2002,8,12]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/0304-4165(86)90237-0"},{"key":"e_1_2_6_3_2","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1182\/blood.V66.5.1086.1086","article-title":"beta 2\u2010Glycoprotein I: a plasma inhibitor of the contact activation of the intrinsic blood coagulation pathway","volume":"66","author":"Schousboe I","year":"1985","journal-title":"Blood"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199907)42:7<1309::AID-ANR1>3.0.CO;2-F"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780390903"},{"key":"e_1_2_6_6_2","first-page":"1894","article-title":"Antibodies to phospholipid\u2010free beta 2\u2010glycoprotein\u2010I in patients with primary antiphospholipid syndrome","volume":"22","author":"Cabral AR","year":"1995","journal-title":"J Rheumatol"},{"key":"e_1_2_6_7_2","first-page":"2131","article-title":"Antibodies to beta 2\u2010glycoprotein I: a potential marker for clinical features of antiphospholipid antibody syndrome in patients with systemic lupus erythematosus","volume":"25","author":"Sanfilippo SS","year":"1998","journal-title":"J Rheumatol"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(92)90049-H"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1649901"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/0049-0172(92)90021-5"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1177\/096120339600500505"},{"key":"e_1_2_6_12_2","first-page":"1802","article-title":"Exclusion criteria for primary antiphospholipid syndrome","volume":"20","author":"Piette JC","year":"1993","journal-title":"J Rheumatol"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1177\/096120339800700233"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780251101"},{"key":"e_1_2_6_15_2","volume-title":"An introduction to categorical data analysis","author":"Agresi A","year":"1996"},{"key":"e_1_2_6_16_2","first-page":"733","article-title":"A reassessment of the antiphospholipid syndrome","volume":"17","author":"Harris EN","year":"1990","journal-title":"J Rheumatol"},{"key":"e_1_2_6_17_2","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1542\/peds.96.6.1040","article-title":"Antiphospholipid antibodies in pediatric systemic lupus erythematosus","volume":"96","author":"Seaman DE","year":"1995","journal-title":"Pediatrics"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(96)70064-1"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.56.3.194"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/34.9.873"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpedi.1994.02170040064011"},{"key":"e_1_2_6_22_2","first-page":"1389","article-title":"The relationship of anticardiolipin antibodies to disease manifestations in pediatric systemic lupus erythematosus","volume":"15","author":"Shergy WJ","year":"1988","journal-title":"J Rheumatol"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1203\/00006450-199809000-00014"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-112-9-682"},{"key":"e_1_2_6_25_2","first-page":"1899","article-title":"Clinical manifestations of the antiphospholipid syndrome in patients with systemic lupus erythematosus associate more strongly with anti\u2010beta 2\u2010glycoprotein\u2010I than with antiphospholipid antibodies","volume":"22","author":"Cabiedes J","year":"1995","journal-title":"J Rheumatol"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/0167-5699(90)90021-Z"},{"key":"e_1_2_6_27_2","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1055\/s-0038-1650686","article-title":"Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with systemic lupus erythematosus: comparison between different assays for the detection of antiphospholipid antibodies","volume":"76","author":"Horbach DA","year":"1996","journal-title":"Thromb Haemost"}],"container-title":["Arthritis Care &amp; Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fart.10510","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.10510","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T03:52:59Z","timestamp":1696996379000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/art.10510"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,8,12]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2002,8,15]]}},"alternative-id":["10.1002\/art.10510"],"URL":"https:\/\/doi.org\/10.1002\/art.10510","archive":["Portico"],"relation":{},"ISSN":["0893-7524","1529-0123"],"issn-type":[{"value":"0893-7524","type":"print"},{"value":"1529-0123","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,8,12]]}}}